Aligos Therapeutics

In case you missed it, our Chairman, President, and CEO, Dr. Lawrence Blatt, discussed our drug candidates in development for the treatment of #MASH and chronic #HepatitisB in this recent Xtalks Life Science Podcast episode. Listen here: https://lnkd.in/gWymv8kv

We’re hosting a virtual KOL event featuring Mark Sulkowski, MD, on July 18 to discuss the unmet need and current treatment landscape for patients with chronic #HepatitisB (CHB), positive data from the Phase 1b study of our CHB candidate, development plans and the chronic suppression regulatory pathway. Learn more: https://lnkd.in/e4yWu2ka

We’re developing drug candidates with clinically validated targets and pharmacologically optimized characteristics for chronic #LiverDiseases and viral infections. Learn more about our approach: https://lnkd.in/gXW8Q9Z8

Our mission is to become the world leader in the development of targeted therapies for #MASH and viral diseases to address important unmet medical needs. Learn more here: https://bit.ly/45jYor3

We are drawing upon our extensive experience to build a pipeline of potentially best-in-class drug candidates for #MASH, chronic #HepatitisB and #COVID19. Learn more about our candidates that target multiple clinically validated mechanisms of action: https://bit.ly/4aY04ru

Today we announced positive data from six poster presentations at the #EASLCongress. These include three clinical posters highlighting the potent antiviral activity of our CAM-E drug candidate for chronic Hepatitis B (CHB) in HBeAg-positive and HBeAg-negative subjects. Read more: https://bit.ly/3X6RTFZ

Did you know we are advancing a CAM-E drug candidate for the treatment of chronic #HepatitisB (CHB) that has potentially best-in-class properties and could play a role in the chronic suppression of the disease? Learn more: https://lnkd.in/gXW8Q9Z8

Our team announced today that we’ve had six abstracts accepted for poster presentations, including two Top abstracts, at the #EASLCongress 2024, being held June 5-8 in Milan, Italy. See more info here: https://lnkd.in/gwW8WCvm EASL | The Home of Hepatology

Today we announced the completion of enrollment in our Phase 2a HERALD study for #MASH, with topline safety and efficacy data anticipated in early Q4 2024. We’ve also welcomed Dr. Rohit Loomba as our Principal Investigator for the study. Read more here: https://lnkd.in/gbujijmt

In case you missed it, we’re currently dosing subjects in our Phase 2a HERALD study for the treatment of #MASH. Read here for more information: https://lnkd.in/epnrr2pk